Nauris Grigals has become a Partner and the Head of Corporate Commercial team at TGS Baltic

03 / 19

Nauris Grigals joined TGS Baltic in 2009. Nauris is a recognized expert in corporate law, commercial law and M&A. He has also broad experience in litigation, especially in the area of corporate and tax litigation, as well as arbitration. In 2019, Nauris has become a Partner at TGS Baltic.

He is an expert with more than 10 years of practice in Corporate/Commercial and M&A, and Dispute Resolution. He advised the European Central Bank in litigations with respect to revocation of banking licence of ABLV Bank and Trasta Komercbanka (EUR 4 billion);

Advised the Ministry of Economics of the Republic of Latvia on the acquisition of 18.31% of the shares of the natural gas transmission and storage system operator AS Conexus Baltic Grid by the Latvian electricity transmission system operator AS Augstsprieguma tīkls from the German energy company Uniper Ruhrgas International GmbH and 16.05% of the shares – from SIA ITERA Latvija (EUR 54 million for 34.36%);

Advised Swedish Bergs Timber AB (publ) on the acquisition of Vika Wood and Byko-lat (Latvia), EWP AS and Laesti AS (Estonia) and Norvik Shipping (United Kingdom) from Iceland Norvik hf. (EUR 70 million);

Assisted with acquisition of SIA IRI Forest Assets Latvia (formerly SIA Foran Real Estate), one of the largest forest companies, from Storebrand Livsforsikring AS, SPP Pension & Försäkring AB (publ), NORSKOG and a private person (value of a comparable transaction EUR 324 million);

Assisted IK Investment Partners ("IK") with acquisition of Carspect AB, SIA Scantest, Autotest Polska Sp. Z.o.o and A-Katsastus OÜ from A-Katsastus Group Oy, a leading vehicle inspection service provider in the Northern Europe;

Ensured legal assistance to AS Luminor bank group during take-over of the pledged assets (EUR 15 million);

Advised FCC, Hochtief and ACB in relation to infrastructure development project in Riga International Airport (EUR 79 million);

Represented the shareholder of a large pharmaceutical production company in a dispute with the Financial and Capital Market Commission in relation to mandatory takeover bid.

Luxe 2